Monitoring | Typical time to onset | Management

AE management

Monitoring

For early identification and management of AEs, a series of follow-up appointments are recommended. Below is a table displaying the recommended follow-up schedule for patients receiving GIOTRIF^® (afatinib) treatment:

Days after start of treatment	Follow-up	Goal
Day 2-3	Phone call or visit^a	Control for early detection of diarrhoea
Day 7	First follow-up visit	Early control of possible class-effect adverse events (diarrhoea and rash)
Day 30 and every cycle	Monthly follow-up visit	Monthly follow-up of patient

Days after start of treatment	Day 2-3	Day 7	Day 30 and every cycle
Follow-up	Phone call or visit^a	First follow-up visit	Monthly follow-up visit
Goal	Control for early detection of diarrhoea	Early control of possible class-effect adverse events (diarrhoea and rash)	Monthly follow-up of patient

^aBy an oncologist or an oncology nurse on the basis of the hospital/centre organisation.

Adapted from Arriola E, et al. 2015.¹

Typical time to onset

Diarrhoea typically has the earliest onset of all common AEs (2-3 days)¹

AE management

Common AEs associated with GIOTRIF^® (afatinib) treatment are generally well managed with supportive care,^3-6 and many of the most common AEs can potentially be managed by dose modification, without compromising efficacy.^7-9 For more information on how some of the most common AEs associated with GIOTRIF^® (afatinib) use can managed, explore the pages below.

AE=Adverse Event

References

1: Arriola E, et al. Future Oncol. 2015;11(2):267–277.
2: Aw DC, et al. Asia-Pac J Clin Oncol 2018;14(1):23–31.
3: Sequist LV, et al. J Clin Oncol. 2013;31(27):3327–3334.
4: Wu YL, et al. Lancet Oncol 2014;15(2):213–222.
5: Park K, et al. Lancet Oncol 2016;17(5):577–589.
6: Soria JC, et al. Lancet Oncol 2015;16(8):897–890.
7: Yang JC, et al. Ann Oncol 2016;27(11):2103–2110.
8: Hirsh V, et al. First-line afatinib versus gefitinib for patients with EGFR mutation-positive NSCLC (LUX-Lung 7): patient-reported outcomes and impact of dose modifications on efficacy and adverse events. ASCO. 3–7 June 2016. Chicago, IL, USA. Poster: 369.
9: Halmos B, et al. Lung Cancer 2019;127:103–111.

You may also be interested in...

Indication

GIOTRIF^® (afatinib) in an irreversible ErbB inhibitor approved in non-small-cell lung cancer. Find out how your patients could benefit.

Learn more

Dosing

GIOTRIF® (afatinib) dose modification can be an important strategy to help manage adverse reactions.

Learn more

This site uses cookies to improve your browsing experience. By using this site, you agree to their use.

Cookie policy

Disclaimer

You're now leaving our website...

Using this link will let you leave a website of Boehringer Ingelheim International GmbH (“BI”) or to a different domain under the control of BI. In the event that the linked site is not under the control of BI but under the control of a third party or an affiliate in the Boehringer Ingelheim group of companies, BI shall not be responsible for the contents, processing of personal data of any linked site or any link contained in a linked site, or any changes or updates to such sites. This link is provided to you only as a convenience, and the inclusion of any link does not imply endorsement by BI of the site.

Do you want to continue?

Continue Cancel

I am a Healthcare Professional outside the US and UK

Click here for international product information intended for Healthcare Professionals about afatinib for non-small-cell lung cancer treatment.

I am not a Healthcare Professional and I am outside the US and the UK

Click here for general international information about afatinib for non-small-cell lung cancer treatment.

Country-specific product information

Click here for country-specific product information intended for Healthcare Professionals about afatinib for non-small-cell lung cancer treatment.